peptide-t-amide and Psoriasis

Peptide T is an octapeptide (ASTTTNYT) from the V2 region of gpl20 of HIV. D-[Ala]-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-amide (DAPTA) is one of its analogue. DAPTA has been shown to resolve the psoriatic lesions. The mechanisms of action of peptide T for its therapeutic effect is not clearly understood. Lymphomononuclear cells play an important roles in inflammatory disease processes. Intraepidermal collection of lymphocytes is a unique feature of the inflammatory processes of psoriasis. It is believed that chemokine such as RANTES (C-C class) plays an important role for intraepidermal localization of the inflammatory infiltrates in psoriasis. In order to study the mechanisms, we have analyzed the effects of DAPTA on monocyte and lymphocyte chemotaxis. Chemotaxis of cells was measured by using Boyden chamber. DAPTA inhibited significantly the monocyte and lymphocyte chemotactic activity of RANTES (p < 0.005, < 0.001). Antichemotactic activities of peptide T analogue could be a possible explanation for its therapeutic efficacy in psoriasis.

Topics: Adult; Chemokine CCL5; Chemotaxis, Leukocyte; Female; Humans; Male; Middle Aged; Monocytes; Peptide T; Psoriasis; T-Lymphocytes

In addition to acquired immunodeficiency syndrome (AIDS), persons infected with human immunodeficiency virus often develop cutaneous manifestations, including severe psoriasis. In previous studies, we have established that psoriatic fibroblasts and erythrocytes obtained from psoriatic patients exhibit decreased levels of cyclic adenosine monophosphate (cAMP) dependent protein kinase (PKA) activity and of 8-azido-[32P]cAMP binding to the RI and RII regulatory subunits of PKA. Because treatment of patients with peptide T (an octapeptide sequence found in the human immunodeficiency virus envelope glycoprotein gp120) has been observed to result in an improvement in the psoriatic condition, studies were initiated to determine if peptide T and gp120 protein treatment of normal and psoriatic human fibroblasts resulted in any changes in PKA. Exposure of psoriatic fibroblasts to peptide T resulted in a time (4 h to 6 d) and dose [10(-14)-10(-8) M] dependent increase in the levels of 8-azido-[32P]cAMP binding to the RI and RII regulatory subunits of PKA, along with a corresponding increase in PKA activity. Peptide T exhibited a biphasic dose dependent response, with maximal effects on PKA noted at 10(-12)M peptide T. Treatment of normal human fibroblasts with peptide T did not result in any change in PKA levels. Conversely, treatment of normal human fibroblasts for 18 h with gp120 protein [10(-13) M] resulted in a significant decrease in the levels of 8-azido-[32P]cAMP binding to RI and RII and in PKA activity. The presence of peptide T blocked this effect of the gp120 protein. These results indicate that peptide T and gp120 protein may inversely alter the intracellular levels of 8-azido-[32P]cAMP binding to RI and RII, and of PKA activity in susceptible cells. These observed changes in the cyclic AMP-PKA signaling pathway, a biochemical marker for psoriasis, may offer some mechanistic insight into the noted beneficial effects of peptide T treatment, including an improvement in psoriatic lesions.

Topics: Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Fibroblasts; HIV Envelope Protein gp120; Humans; Peptide T; Psoriasis; Reference Values; Skin